dispatches from DCAT Week '16

AAI and CML rebrand as Alcami

By Melissa Fassbender

- Last updated on GMT

Alcami CEO Stephan Kutzer announcing the firm's new brand at DCAT Week
Alcami CEO Stephan Kutzer announcing the firm's new brand at DCAT Week

Related tags: Generic drug, Pharmacology

AAI Pharma Services (AAI) and Cambridge Major Laboratories (CML) have rebranded as Alcami, a contract development and manufacturing organization. 

I’m very excited to announce today here in NYC … from today on we will go by the name Alcami​,” said Stephan Kutzer said at a press conference during DCAT Week 16’*.  “It is a very exciting time for us.”

While the companies originally joined in late 2013​ in order to offer analytical testing and development services for APIs with oral solid and parenteral dose finished product capacity, the companies believe the new unified identity will provide customers with a greater outsourcing offering.

The company is headed by a new leadership team, as well as a new commercial team. Additionally, most of the operational organization has been changed.

Kuzer stressed not only the company’s new name, but the period at the end.

There is something to be said about this period,”​ he said. “It comes down to end-to-end services in the pharma industry​.”

But why Alcami?

Alcami is another way of saying for AAI, CML, according to Kutzer - It is pays homage to the company’s past, while looking towards the future.

It’s about transformation of an organization, of a service​,” he added.

According to Kutzer, the company has “very interesting, prosperous growth plans.”

This growth will be driven by the company’s end-to-end services; however, Kutzer notes that individual services are available as well, as everything can also be done independently.

Kutzer also noted the companies US-base as a key to Alcami’s past and future success.

There’s a lot of interest in local services​,” he said. “We are a US based manufacturing player, and that is a key advantage​.”

Alcami will provide drug substance and drug development capabilities from solid state chemistry to formulation.

The company will also be relocating from its St. Louis Analytical Testing Services to a new facility at the Cortex innovation Center.

*DCAT Week is hosted by the Drug, Chemical & Associated Technologies Association (DCAT), a not-for-profit, member-supported, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies.

Related topics: Contract Manufacturing

Related news

Show more

Related products

show more


Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers

Follow us


View more